Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report

References

• GazdarAFActivating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
   PubMedGoogle Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MurraySDahabrehIJLinardouHManoloukosMBafaloukosDKosmidisPSomatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small-cell lung cancer: an analytical databaseJ Thorac Oncol20083883283918670300
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• TsengYHTsengYCLinYHEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment and salvage chemotherapy in EGFR-mutated elderly pulmonary adenocarcinoma patientsOncologist201520775876626054633
   PubMedGoogle Scholar
• TanakaTMatsuokaMSutaniAFrequency of and variables associated with the EGFR mutation and its subtypesInt J Cancer2010126365165519609951
   PubMed Web of Science ®Google Scholar
• BarlesiFMazieresJMerlioJPBiomarkers France contributorsRoutine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Lancet2016387100261415142626777916
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• DouillardJYOstorosGCoboMFirst-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm studyBr J Cancer20141101556224263064
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsClin Oncol2013312733273334
   Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• SocinskiMVillaruzLRossJUnderstanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progressionOncologist201722131127821794
   PubMedGoogle Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2011Based on November; 2013 SEER data submission, posted to the SEER website, April 2014Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/csr/1975_2011/Accessed November 1, 2015
   Google Scholar
• Van DammeVGovaertsENackaertsKDoomsCWautersIVansteenkisteJClinical factors predictive of long-term survival in advanced non-small cell lung cancerLung Cancer2013791737623083516
   PubMedGoogle Scholar
• OzkayaSFindikSDiricanAAticiAGLong-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabineExp Ther Med2012461035103823226770
   PubMedGoogle Scholar
• LinJJCardarellaSLydonCAFive-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIsJ Thorac Oncol201611455656526724471
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMNorth-East Japan Study GroupUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• YoshiokaHMitsudomiTMoritaSFinal overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol201432Suppl8117
   Google Scholar
• LeeCKBrownCGrallaRJImpact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisJ Natl Cancer Inst2013105959560523594426
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• ShigematsuHGazdarAFSomatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInt J Cancer2006118225726216231326
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• HaalandBTanPSde CastroGJrLopesGMeta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutationsJ Thorac Oncol20149680581124787964
   PubMed Web of Science ®Google Scholar
• TakedaMNakagawaKToxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancerMol Clin Oncol2017613628123721
   PubMed Web of Science ®Google Scholar
• SchneiderCPHeigenerDSchott-von-RömerKEpidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST studyJ Thorac Oncol20083121446145319057271
   PubMed Web of Science ®Google Scholar
• BenedettiGLatiniLGalettaDColucciGCrinòLEpidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinibJ Thorac Oncol20094793693719550250
   PubMedGoogle Scholar
• YosukeTKatsuhiroMMasahideFEfficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutationCancer Chemother Pharmacol20116841089109221681573
   PubMedGoogle Scholar
• von PawelJWagnerHDuellTPoellingerBErlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reportsOnkologie200831312312618322416
   PubMedGoogle Scholar
• RielyGJPaoWPhamDClinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibClin Cancer Res2006123 Pt 183984416467097
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYSequistLVExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibClin Cancer Res200612133908391416818686
   PubMed Web of Science ®Google Scholar
• WeberBSorensenBSKnapMMMadsenHHNexoEMeldgaardPComplete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinibJ Thorac Oncol20116111946194922005472
   PubMedGoogle Scholar
• HeskethPJChanskyKWozniakAJSouthwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2J Thorac Oncol2008391026103118758306
   PubMed Web of Science ®Google Scholar
• LinCCYangCHEpidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerTarg Oncol2009413744
   PubMedGoogle Scholar
• FerteCBesseBDansinEDurable responses to erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinomaAnn Oncol20102161385138720501506
   PubMedGoogle Scholar
• LaraPNMoonJHeskethJSWOG S0709: randomized phase II trial of erlotinib versus erlotinib plus carboplatin/paclitaxel in patients with advanced non-small cell lung cancer and impaired performance status as selected by a serum proteomics assayJ Thorac Oncol201611342042526725184
   PubMed Web of Science ®Google Scholar
• YangJA Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901)Oral presentation at: WCLC 2015,16th World Conference on Lung CancerSeptember 8, 2015Denver, CO, USA Available from: https://library.iaslc.org/search-speaker?search_speaker=25092Accessed August 22, 2017
   Google Scholar
• GoldbergSBOxnardGRDigumarthySChemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsOncologist201318111214122024072220
   PubMed Web of Science ®Google Scholar